Medical Economics overhauls team

Share this article:
Advanstar's Medical Economics title announced the hiring of new senior-level editors. The editorial team is now located in Cleveland, Ohio. The magazine was formerly headquartered in Woodcliff Lake, NJ.

New editorial staff at Medical Economics is as follows:
  • Erich Burnett, editor in chief, who spent the last 12 years at Village Voice Media, where he was fourth-ranking editorial officer; 
  • Ken Krizner, managing editor, a 20-year veteran of the publishing industry; 
  • Bob Feigenbaum, articles editor, previously editor-in-chief at Physician's Management magazine; 
  • Brandon Glenn, senior editor, formerly a reporter at Crain's Chicago Business; and 
  • Morgan Lewis Jr., senior editor, previously a senior editor at Inside Business magazine.

The announcement follows a merging of several Advanstar titles—including Medical Economics—into the Healthcare Centralized Content Group last April. Drug Topics, Formulary, Managed Healthcare Executive and Geriatrics are also included in the group. 

The Healthcare Centralized Content Group delivers customized content from the aforementioned titles through print, multimedia and e-media platforms.

The editorial team at Medical Economics will report to Tara Stultz, executive editorial director, Primary Care and Healthcare Centralized Content Group, according to a statement.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?